Rejyonel Sitrat Antikoagülasyonu

Alvarez G, Chrusch C, Hulme T, et al. Renal replacement therapy: a practical update. Can J Anaesth 2019; 66:593‐604.

Balogun RA, Turgut F, Caldwell S, et al. Regional citrate anticoagulation in critically ill patients with liver and kidney failure. J Nephrol 2012; 25:113‐9.

Durão MS, Monte JC, Batista MC, et al. The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury. Crit Care Med 2008; 36: 3024‐9.

Faybik P, Hetz H, Mitterer G, et al. Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med 2011; 39:273‐9.

Fealy N. Regional Citrate Anticoagulation. In: Kellum A; ed. Continuous Renal Replacement Therapy. 2nd ed. Oxford University Press. 2016;151-4.

Galvin Z, McDonough A, Ryan J, et al. Blood alanine aminotransferase levels >1,000 IU/l - causes and outcomes. Clin Med (Lond) 2015; 15:244‐7.

Hetzel GR, Taskaya G, Sucker C, et al. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2006; 48:806‐11.

Ho KM, Pavey W. Applying the cell-based coagulation model in the management of critical bleeding. Anaesth Intensive Care 2017; 45:166-76.

Honore PM, De Bels D, Preseau T, et al. Citrate: how to get started and what, when, and how to monitor? J Transl Int Med 2018; 6:115‐27.

Kalb R, Kram R, Morgera S, et al. Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk. Ther Apher Dial 2013; 17:202‐12.

Khadzhynov D, Dahlinger A, Schelter C, et al. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation. Crit Care Med 2017;45: e941‐6.

Kindgen-Milles D, Brandenburger T, Dimski T. Regional citrate anticoagulation for continuous renal replacement therapy. Curr Opin Crit Care 2018; 24:450-4.

Klingele M, Seiler S, Poppleton A, et al. The gap between calculated and actual calcium substitution during citrate anticoagulation in an immobilised patient on renal replacement therapy reflects the extent of bone loss - a case report. BMC Nephrol 2014; 15:163.

Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31:2450‐5.

Lanckohr C, Hahnenkamp K, Boschin M. Continuous renal replacement therapy with regional citrate anticoagulation: do we really know the details?. Curr Opin Anaesthesiol 2013; 26:428-37.

Liu C, Mao Z, Kang H, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care 2016; 20:144.

Morabito S, Pistolesi V, Tritapepe L, et al. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol 2014; 9:2173‐88.

Morabito S, Pistolesi V, Tritapepe L, et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care 2012;16: R111.

Morgera S, Schneider M, Slowinski T, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009; 37: 2018‐24.

Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37:545‐52.

Park JS, Kim GH, Kang CM, et al. Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration. Korean J Intern Med 2011; 26:68‐75.

Raimundo M, Crichton S, Lei K, et al. Maintaining normal levels of ionized calcium during citrate-based renal replacement therapy is associated with stable parathyroid hormone levels. Nephron Clin Pract 2013; 124:124‐31.

Ricci D, Panicali L, Facchini MG, et al. Citrate anticoagulation during continuous renal replacement therapy. Contrib Nephrol 2017; 190:19‐30.

Schneider AG, Journois D, Rimmele T. Complications of regional citrate anticoagulation: accumulation or overload? Crit Care 2017; 21:281.

Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care 2015; 19:349.

Tan JN, Haroon SWP, Mukhopadhyay A, et al. Hyperlactatemia predicts citrate intolerance with regional citrate anticoagulation during continuous renal replacement therapy. J Intensive Care Med 2019; 34:418‐25.

Tsujimoto H, Tsujimoto Y, Nakata Y, et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev 2020;3:CD012467.

Weinberg JM, Venkatachalam MA, Roeser NF, et al. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. Proc Natl Acad Sci USA 2000; 97:2826‐31.

Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care 2019; 23:22.

Alvarez G, Chrusch C, Hulme T, et al. Renal replacement therapy: a practical update. Can J Anaesth 2019; 66:593‐604.

Balogun RA, Turgut F, Caldwell S, et al. Regional citrate anticoagulation in critically ill patients with liver and kidney failure. J Nephrol 2012; 25:113‐9.

Durão MS, Monte JC, Batista MC, et al. The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury. Crit Care Med 2008; 36: 3024‐9.

Faybik P, Hetz H, Mitterer G, et al. Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med 2011; 39:273‐9.

Fealy N. Regional Citrate Anticoagulation. In: Kellum A; ed. Continuous Renal Replacement Therapy. 2nd ed. Oxford University Press. 2016;151-4.

Galvin Z, McDonough A, Ryan J, et al. Blood alanine aminotransferase levels >1,000 IU/l - causes and outcomes. Clin Med (Lond) 2015; 15:244‐7.

Hetzel GR, Taskaya G, Sucker C, et al. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2006; 48:806‐11.

Ho KM, Pavey W. Applying the cell-based coagulation model in the management of critical bleeding. Anaesth Intensive Care 2017; 45:166-76.

Honore PM, De Bels D, Preseau T, et al. Citrate: how to get started and what, when, and how to monitor? J Transl Int Med 2018; 6:115‐27.

Kalb R, Kram R, Morgera S, et al. Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk. Ther Apher Dial 2013; 17:202‐12.

Khadzhynov D, Dahlinger A, Schelter C, et al. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation. Crit Care Med 2017;45: e941‐6.

Kindgen-Milles D, Brandenburger T, Dimski T. Regional citrate anticoagulation for continuous renal replacement therapy. Curr Opin Crit Care 2018; 24:450-4.

Klingele M, Seiler S, Poppleton A, et al. The gap between calculated and actual calcium substitution during citrate anticoagulation in an immobilised patient on renal replacement therapy reflects the extent of bone loss - a case report. BMC Nephrol 2014; 15:163.

Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31:2450‐5.

Lanckohr C, Hahnenkamp K, Boschin M. Continuous renal replacement therapy with regional citrate anticoagulation: do we really know the details?. Curr Opin Anaesthesiol 2013; 26:428-37.

Liu C, Mao Z, Kang H, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care 2016; 20:144.

Morabito S, Pistolesi V, Tritapepe L, et al. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol 2014; 9:2173‐88.

Morabito S, Pistolesi V, Tritapepe L, et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care 2012;16: R111.

Morgera S, Schneider M, Slowinski T, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009; 37: 2018‐24.

Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37:545‐52.

Park JS, Kim GH, Kang CM, et al. Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration. Korean J Intern Med 2011; 26:68‐75.

Raimundo M, Crichton S, Lei K, et al. Maintaining normal levels of ionized calcium during citrate-based renal replacement therapy is associated with stable parathyroid hormone levels. Nephron Clin Pract 2013; 124:124‐31.

Ricci D, Panicali L, Facchini MG, et al. Citrate anticoagulation during continuous renal replacement therapy. Contrib Nephrol 2017; 190:19‐30.

Schneider AG, Journois D, Rimmele T. Complications of regional citrate anticoagulation: accumulation or overload? Crit Care 2017; 21:281.

Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care 2015; 19:349.

Tan JN, Haroon SWP, Mukhopadhyay A, et al. Hyperlactatemia predicts citrate intolerance with regional citrate anticoagulation during continuous renal replacement therapy. J Intensive Care Med 2019; 34:418‐25.

Tsujimoto H, Tsujimoto Y, Nakata Y, et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev 2020;3:CD012467.

Weinberg JM, Venkatachalam MA, Roeser NF, et al. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. Proc Natl Acad Sci USA 2000; 97:2826‐31.

Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care 2019; 23:22.